Regulating visceral fat through gut microbiota (1)

In contrast to the commonly available market interventions that focus on "blocking" or "satiety-inducing" exogenous substances, the correlation between gut microbiota and obesity, as well as related metabolic disorders, has been established. Significant differences exist in the gut microbiota composition between obese and non-obese individuals, and the association between leptin resistance and gut microbiota has also been confirmed. Thus, the regulation of gut microbiota represents a micro-mechanism for fat reduction.

Improving "glucose and lipid metabolism" and alleviating "leptin resistance" can fundamentally adjust bodily functions and reduce visceral fat accumulation.

Visceral fat obesity, compared to subcutaneous fat obesity, causes damage to various organs, leading to endogenous metabolic disorders. Therefore, merely increasing caloric expenditure through exercise is insufficient to reduce visceral fat.

Bioyitech focuses on "glucose and lipid metabolism" with its probiotic solution for visceral fat reduction, which combines multiple functional strains that regulate metabolism through micro-mechanisms. This approach stimulates the body's intrinsic repair capabilities and alleviates leptin resistance. Additionally, it aids in restoring gut microbiota balance, minimizing the impact of harmful bacteria on the body, and reducing visceral fat accumulation at its source.

Core strain testing of the program

An animal study observed the effects of Lactobacillus plantarum F3-2 on body fat metabolism.

The results indicate that after a 12-week intervention, the weight gain in mice subjected to Lactobacillus plantarum F3-2 was significantly lower than that observed in the high-fat diet group, demonstrating an effect comparable to that of orlistat (the only over-the-counter weight loss medication approved by the FDA in the United States, EMA in the European Union, and the National Medical Products Administration in China).

Note: A high-fat diet significantly increases the average size of epididymal adipocytes. After the F3-2 intervention, the morphology of epididymal adipocytes in mice improved, with a reduction in cell size and an increase in the number of smaller cells.

Epididymal adipose tissue is classified as a type of white adipose tissue. In the human body, white adipose tissue is predominantly located around the abdominal area, characterizing the "abdominal obesity" phenotype.

Additionally, experiments revealed that F3-2 effectively reduced serum triglycerides and total cholesterol, with decreases of 42.14% and 41.41%, respectively, compared to the high-fat group (p<0.05). Furthermore, it demonstrated a significant inhibitory effect on the increase in liver weight, with no significant difference in intervention effects compared to the positive control group treated with orlistat (p>0.05).

By analyzing the levels of key lipid metabolites and major short-chain fatty acids in the adipose tissue of the experimental group, we further verified the regulatory mechanism of F3-2:

Note: Compared with the high-fat group, F3-2 significantly increased the expression of GPR43 gene (p<0 .05); PPARγ gene expression was significantly slowed down and was not statistically different from the positive drug orlistat intervention group (p<0 .05).

Lactobacillus plantarum F3-2 accelerates lipid metabolism by "activating GPR43" while "inhibiting PPARγ" to slow down lipid accumulation, thereby enhancing glucose and lipid metabolism, improving the GLP-1 signaling pathway, and alleviating leptin resistance, ultimately leading to a fundamental improvement in body fat metabolism.